Juniper Pharmaceuticals Names Dr. Mary Ann Gray to Board

On March 23, 2016, the Board of Directors (the "Board") of Juniper Pharmaceuticals, Inc. CBRX appointed Dr. Mary Ann Gray as a new director of the Company, upon the recommendation of its Nominating and Governance Committee, effective immediately. Dr. Gray will serve until the Company's 2016 annual meeting of stockholders (where she will be nominated for reelection by the stockholders of the Company). Our Board believes that Dr. Gray's strong dual background as a scientist and financial analyst and portfolio manager in the biotechnology industry, as well as her public company board experience qualify her to serve on our Board. Dr. Gray will also serve as Chairman of the Audit Committee. Since 2003, Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic advice to both public and private biotechnology companies. Previously, she spent three and a half years with the Federated Kaufmann Fund focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell-side biotechnology analyst for nine years with Kidder Peabody, Dillon Read and Raymond James. Earlier in her career, Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in hospital laboratory. Dr. Gray also serves on the board of directors of three public biotechnology companies, Acadia Pharmaceuticals, Inc. ("Acadia"), since 2005, Senomyx, Inc. ("Senomyx"), since 2010, and TetraLogic Pharmaceuticals Corporation ("TetraLogic"), since 2014. At Acadia she serves as chairman of the audit committee and also serves on the compensation committee. At Senomyx she is a member of the compensation committee. At TetraLogic she is chairman of the audit committee. Dr. Gray also served on the board of directors of Dyax Corp., beginning in 2001, and served as its lead director from 2010 until January 2016, when Dyax Corp. was acquired by Shire plc. Dr. Gray has a Ph.D. in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer. She did post-doctoral work at Northwestern University Medical School and Yale University School of Medicine. She held scientific positions at Schering Plough and NeoRx Corporation. As previously disclosed, in the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2015, Donald Hunter received fewer votes for election to our Board of Directors than votes against election at our 2015 annual meeting of stockholders. Pursuant to the Company's Amended and Restated Bylaws, Mr. Hunter submitted his resignation to the Board. The Board accepted Mr. Hunter's resignation and determined to undertake a search for a qualified successor. Mr. Hunter's resignation became effective upon Dr. Gray's appointment to the Board. The Board is grateful for Mr. Hunter's service to the Company.